Conflict of interest

NS-87/CPX-351 was provided by Nippon Shinyaku Co., Ltd. UK reports grants from Astellas Pharma Inc., Abbvie Inc., Bristol-Myers-Squibb K.K., Janssen Pharmaceutical K.K., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Yakult Honsha Co., Ltd., Merck & Co., Inc., SymBio Pharmaceuticals Limited., Celgene Corporation., Daiichi Sankyo Company Limited., Sumitomo Pharma Co., Ltd., Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Mundipharma International., and Takeda Pharmaceutical Company Limited., consulting fees from Astellas Pharma Inc., Amgen Inc., Alnylam Japan K.K., Alexion Pharmaceuticals, Inc., Incyte Corporation., Ono Pharmaceutical Co., Ltd., OHARA Pharmaceutical Co.,Ltd., Kyowa Kirin Co., Sanofi K.K., Sandoz International GmbH, SymBio Pharmaceuticals Limited., Takeda Pharmaceutical Company Limited., Chugai Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd., and honoraria from Novartis Pharma K.K., Abbvie Inc., Alexion Pharmaceuticals, Inc., Incyte Corporation., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company Limited., Nippon Shinyaku Co., Ltd., Pfizer Japan Inc., and Bristol-Myers-Squibb K.K. AK reports grants from Chugai Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited., Kyowa Kirin Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. YO reports grants from Alexion Pharmaceuticals, Inc. and honoraria from Novartis Pharma K.K. OM reports honoraria from Astellas Pharma Inc., Daiichi Sankyo Company Limited., Otsuka Pharmaceutical Co., Ltd., and Nippon Shinyaku Co., Ltd. YT reports consulting fees and honoraria for lectures and speakers. KH reports grants from FUJIFILM Pharmaceuticals Inc., Kyowa Kirin Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Perseus Proteomics Inc., Daiichi Sankyo Company Limited., Abbvie Inc., CURED, Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Holdings Co., Ltd., Nippon Shinyaku Co., Ltd., and Takeda Pharmaceutical Company Limited., Sumitomo Pharma Co., and honoraria from Abbvie Inc., Chugai Pharmaceutical Co., Ltd., Astellas Pharma Inc., and Novartis Pharma K.K. IT reports honoraria from Asahi Kasei Pharma Corp., Sanofi K.K., Nippon Shinyaku Co., Ltd., Alexion Pharmaceuticals, Inc., and Pfizer Japan Inc., and participation on an advisory board for Chugai Pharmaceutical Co., Ltd., Alexion Pharmaceuticals, Inc., and Asahi Kasei Pharma Corp. AN reports grants from Novartis Pharma K.K. and honoraria from Abbvie Inc. OS reports honoraria from Novartis Pharma K.K., Bristol-Myers-Squibb K.K., Takeda Pharmaceutical Company Limited., AstraZeneca K.K., Janssen Pharmaceutical K.K., Abbvie Inc., and Amgen Inc.

AK reports research funding of the submitted study from Nippon Shinyaku Co., Ltd., grants from Otsuka Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Asahi Kasei Pharma Corp., Abbvie Inc., Chugai Pharmaceutical Co., Ltd., and Takeda Pharmaceutical Company Limited., and honoraria from Abbvie Inc., Eisai Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Pfizer Japan Inc., Bristol-Myers-Squibb K.K., and Janssen Pharmaceutical K.K.

MY reports research funding of the submitted study from Nippon Shinyaku Co., Ltd., honoraria from Nippon Shinyaku Co., Ltd., Novartis Pharma K.K., Astellas Pharma Inc., and Abbvie Inc., and leadership in Japan Adult Leukemia Study Group. DA, MK, IS, and KU are employees of Nippon Shinyaku Co., Ltd.

Data availability

All data generated or analyzed during this study are included in this published article and its supplementary information files.